| Identification | Back Directory | [Name]
L371,257 | [CAS]
162042-44-6 | [Synonyms]
L371,257
1-[1-[4-(1-acetylpiperidin-4-yl)oxy-2-methoxybenzoyl]piperidin-4-yl]-4H-3,1-benzoxazin-2-one
1-[4-[(1-Acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]-4-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)piperidine
2H-3,1-Benzoxazin-2-one, 1-[1-[4-[(1-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]-4-piperidinyl]-1,4-dihydro- | [Molecular Formula]
C28H33N3O6 | [MDL Number]
MFCD00944944 | [MOL File]
162042-44-6.mol | [Molecular Weight]
507.58 |
| Chemical Properties | Back Directory | [Boiling point ]
728.9±60.0 °C(Predicted) | [density ]
1.282±0.06 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
Soluble to 10 mM in DMSO with gentle warming | [form ]
Powder | [pka]
0.73±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
L-371,257 is a potent antagonist of oxytocin-induced contractions of the rat uterus in vitro and in vivo and has significant oral bioavailability in rats. | [Biological Activity]
Potent, high affinity human oxytocin (OT) receptor antagonist (K i = 4.6 nM) that displays > 800-fold selectivity over human arginine vasopressin receptors V 1a and V 2 . Antagonizes oxytocin-induced contractions in isolated rat uterine tissue (pA 2 = 8.44) and in anesthetised rats following intravenous and intraduodenal administration. Orally active. | [storage]
Store at RT |
|
|